Skip to main content
SpringerLink
Log in

Prostate cancer patients’ report on communication about endocrine therapy and its association with adherence

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Endocrine therapy is a mainstay of prostate cancer therapy. Given that few data exist on patient physician communication with regard to this field of therapy and adherence, we conducted a survey of patient members of a German support organization.

Patients and methods

We developed a structured questionnaire that was tested in a pilot version and then programmed as an online questionnaire.

Results

The questionnaire was completed by 694 patients. While 58 % of participants rated the information they received as comprehensive, 42 % did not. Fifty-one percentage stated that they were informed of side effects in detail, and 35 % received information on supportive treatments available in the event of side effects. Patients with higher education more often reported receiving information on side effects (p = 0.036) as well as alternatives for treatment (p = 0.001). Only 13 % stated that their questions were answered in detail, with 43 % receiving no answers or only non-detailed answers. Additional information was sought by 82 %, mostly from the Internet (67 %) and patient support groups (66 %). Seventy-six percentage experienced side effects that imposed limitations on their daily activities. Of those patients with side effects, 60 % reported that their physicians did not react to their complaints. There is a significant association between side effects in general and depression in particular and non-adherence (p < 0.01 and p = 0.002, respectively). In contrast, better information on side effects is associated with better adherence (p < 0001).

Conclusion

In order to improve adherence, detailed information on side effects and comprehensive supportive care is most important. Physicians should not rely on written information but should rather mainly engage in direct communication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20(1):15–21

    Article  PubMed  Google Scholar 

  • Bourke L, Kirkbridge P, Hooper R, Rosario AJ, Chico TJA, Rosario DJ (2013) Endocrine therapy in prostate cancer: time fr reappraisal of risks, benefits and cost-effectiveness? Brit J Cancer 108(9):13

    Google Scholar 

  • Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890

    Article  PubMed  CAS  Google Scholar 

  • Gueth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491–499

    Article  CAS  Google Scholar 

  • Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S (2006) Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4(9):687–696

    PubMed  Google Scholar 

  • https://www.healthonnet.org/HONcode/German/. Assessed 27 July 2014

  • http://www.krebsgesellschaft.de/download/2009-pl-pca.pdf. Assessed 27 July 2014

  • http://www.krebsgesellschaft.de/download/patientenleitlinie_prostatakrebs_2_2013.pdf. Assessed 27 July 2014

  • http://www.discern.org.uk/discern_instrument.php. Assessed 27 July 2014

  • Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms; Langversion 3.1–2. Aktualisierung, Oktober 2014; AWMF-RegisterNummer 043/022OL

  • Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019

    PubMed  Google Scholar 

  • Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Mottet N, Peneau M, Mzeron JJ, Molinie V, Richaud P (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62(2):213–219

    Article  PubMed  Google Scholar 

  • Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506

    PubMed  Google Scholar 

  • Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 105(11):1628–1634

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Steckelberg A, Berger B, Köpke S, Heesen C, Muehlhauser I (2005) Kriterien für evidenzbasierte Patienteninformationen. Z ärztl Fortb Qualitätssich 99:343–351

    Google Scholar 

  • Studer U, Whelan P, Albrecht W, Casselman J, Reijke TMD, Knoenageö H, Madersbacher S, Isorna S, Sundaram SK, Collette L (2011) Long term results of immediate versus deferred deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891). J Urol 185(4S):e144

    Article  Google Scholar 

  • Widmarl A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD (2009) Endocrine treatment with or without radiotherapy, in locally advances prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308

    Article  Google Scholar 

  • Wuensch P, Hahne A, Haidinger R, Meißler K, Tenter B, Stoll C, Senf B, Huebner J (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141(1):55–60

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Working Group Integrative Oncology, Dr. Senckenberg Chronomedical Institute, J.W. Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    B. Jung & J. Huebner

  2. Clinic Herzoghoehe Bayreuth, Kulmbacherstraße 103, 95445, Bayreuth, Germany

    C. Stoll

  3. Bundesverband Prostatakrebs Selbsthilfe e. v., Haus der Krebsselbsthilfe, Thomas-Mann-Str. 40, 53111, Bonn, Germany

    G. Feick

  4. RNS Praxisgemeinschaft GbR, Beethovenstraße 20, 65189, Wiesbaden, Germany

    F. J. Prott

  5. Interaktiv GmbH, Max-Planck-Straße 6-8, 50858, Cologne, Germany

    J. Zell

  6. German Cancer Society, Kuno-Fischer-Str 8, 14057, Berlin, Germany

    I. Rudolph

Authors
  1. B. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Feick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. J. Prott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Zell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Rudolph
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Huebner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Huebner.

Ethics declarations

Conflict of interest

The authors declare that they do have no conflicts of interest.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. According to the regulations of the ethics committee of the University Hospital Frankfurt/Main for anonymous surveys, no ethics evaluation was necessary. As it was an anonymous survey, no written informed consent was obtained from the participants who voluntarily took part.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jung, B., Stoll, C., Feick, G. et al. Prostate cancer patients’ report on communication about endocrine therapy and its association with adherence. J Cancer Res Clin Oncol 142, 465–470 (2016). https://doi.org/10.1007/s00432-015-2059-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-2059-2

Keywords

Search

Navigation